Description
Date/Time: 04-05-2018 - Thursday - 05:00 PM - 07:00 PM
Jose Sarabia-Sainz1 María Anguiano-Lizarraga1 Nayelli Teran-Saavedra1 Alexel Burgara-Estrella1 Erika Silva-Campa1 Aracely Angulo-Molina1 Daniel Fernández-Quiroz1 Martín Pedroza-Montero1

1, Universidad de Sonora, Hermosillo, , Mexico

Worldwide, cancer represents one of the most important health problems, that is why new research is being carried out to find effective treatments for this condition. Likewise, it seeks for nano-transporters to provide controlled drugs release and also be tissue-specific in order to minimize side effects in the patient, and ensure the success of cancer therapy. In the specific case for liver cancer, specific transporters can be obtained because the hepatocytes present an asialoglycoprotein receptor, which recognizes structures with galactose. In this work, we modified bovine serum albumin (BSA) with lactose by different methods in order to obtain a matrix able to be bio-recognized by the asyloglycoprotein receptor in liver cancer. The modification of BSA was analyzed by electrophoresis, infrared spectroscopy and fluorescence, as well as biorecognition tests with Riccinus comunis agglutinin I (RCA). The results showed that of the three different modifications of BSA were highly recognized by RCA I which indicates the presence of galactose. Subsequently, with the glycoproteins obtained, nanoparticles were synthesized, which were evaluated by means of dynamic light scattering (DLS), Z potential and electronic scanning spectroscopy (SEM). Biorecognition tests of glyconanoparticles were performed using cancer cells from liver (HepG2) and cells from cervical cancer (HeLa) as control. The results indicated the specific interaction of the nanoparticles with HepG2 cells, demonstrating that they could be used as transport for an antitumor drug.

Meeting Program
poster-icon

5:00 PM–7:00 PM Apr 5, 2018 (America - Denver)

PCC North, 300 Level, Exhibit Hall C-E